Muscarinic receptor binding changes in postmortem Parkinson’s disease
Parkinson’s disease (PD) is a devastating disorder, affecting approximately 2% of people aged 60 and above. It is marked by progressive neurodegeneration that has long been known to impact dopaminergic cells and circuits, but more recently the acetylcholine system has also been implicated in the complex aetiology and symptomatology of the disease. While broad changes in cholinergic markers have been described, insight into the contribution of specific acetylcholine receptors is less clear. To address this important unknown, in this study we performed [3H] pirenzepine, [3H] 4DAMP, and [3H] AF-DX 384 in situ radioligand binding on postmortem tissues from Brodmann’s area 6, 9, 46, and the caudate putamen, from PD and matched controls to detect muscarinic M1, M3, and M1/2/4 receptors, respectively. We found no difference in [3H] pirenzepine binding between PD and controls across all regions assessed. [3H] 4DAMP binding was found to be higher in PD CPu and BA9 than in controls. [3H] AF-DX 384 was higher in BA9 of PD compared with controls. In sum, we show selective increase in M3 receptors in cortical and subcortical regions, as well as increased M2/M4 in cortical area BA9, which together support a role for cholinergic dysfunction in PD.
KeywordsParkinson’s disease Acetylcholine Muscarinic receptor Postmortem Human
We would like to thank the families of the subjects for donating the tissue used in these studies. Human brain tissues were received from the Victorian Brain Bank Network, supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian Forensic Institute of Medicine, and funded by Australia’s National Health & Medical Research Council and Parkinson’s Victoria. We would also like to thank Andrew Gibbons, Natalie Thomas, and Won Je Jeon for their input on the radioligand binding methodology.
Compliance with ethical standards
CEM was supported by an NHMRC overseas biomedical research fellowship (APP628906), a Brain and Behavior Research Foundation Young Investigator Award (19543), while these studies were being performed. BD is an NHMRC Senior Research Fellow (APP1002240). This work was supported in part by NHMRC Project Grants (APP1045619, APP628699, and APP1066144), the Victorian Government’s Operational Infrastructure Support, and the Rebecca Cooper Medical Research Foundation. ES was supported by an ARC future fellowship (FT100100689). The funding sources were not involved in the study design; in the collection, the analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
Conflict of interest
The authors have no conflicts of interest to declare.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed, and all procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
- Bymaster FP, Carter PA, Zhang L, Falcone JF, Stengel PW, Cohen ML, Shannon HE, Gomeza J, Wess J, Felder CC (2001) Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice. Life Sci 68(22–23):2473–2479CrossRefPubMedGoogle Scholar
- Colloby SJ, Pakrasi S, Firbank MJ, Perry EK, Piggott MA, Owens J, Wyper DJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT (2006) In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia. NeuroImage 33(2):423–429. doi: 10.1016/j.neuroimage.2006.07.026 CrossRefPubMedGoogle Scholar
- Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann’s areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158(6):918–925. doi: 10.1176/appi.ajp.158.6.918 CrossRefPubMedGoogle Scholar
- Dean B, Pavey G, Chai SY, Mendelson FAO (1999) The localisation and quantification of molecular changes in the human brain using in situ radioligand binding and autoradiography. In: Dean B, Kleinman JE, Hyde TM (eds) Using CNS tissue in psychiatric research. Harwood Academic Press, Sydney, pp 67–83Google Scholar
- Dencker D, Thomsen M, Wortwein G, Weikop P, Cui Y, Jeon J, Wess J, Fink-Jensen A (2012) Muscarinic acetylcholine receptor subtypes as potential drug targets for the treatment of schizophrenia, drug abuse and Parkinson’s disease. ACS Chem Neurosci 3(2):80–89. doi: 10.1021/cn200110q CrossRefPubMedGoogle Scholar
- Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518. doi: 10.1056/NEJMoa041470 CrossRefPubMedGoogle Scholar
- Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T, Koulousakis A, Maguire RP, Pruim J, de Jong BM, Herholz K, Sturm V, Heiss WD, Leenders KL (2005) Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 76(9):1217–1221. doi: 10.1136/jnnp.2004.057893 CrossRefPubMedPubMedCentralGoogle Scholar
- Jeon WJ, Gibbons AS, Dean B (2013) The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 47:7–12. doi: 10.1016/j.pnpbp.2013.08.001 CrossRefPubMedGoogle Scholar
- Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, Perry RH, Perry EK, Wyper D (2004) Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 29(1):108–116. doi: 10.1038/sj.npp.1300302 CrossRefGoogle Scholar
- Poulin B, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, Kong KC, Bottrill A, Mistry S, Wess J, Rosethorne EM, Charlton SJ, Tobin AB (2010) The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci USA 107(20):9440–9445. doi: 10.1073/pnas.0914801107 CrossRefPubMedPubMedCentralGoogle Scholar
- Salamone JD, Correa M, Carlson BB, Wisniecki A, Mayorga AJ, Nisenbaum E, Nisenbaum L, Felder C (2001) Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci 68(22–23):2579–2584CrossRefPubMedGoogle Scholar
- Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T (1999) Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy. Ann Neurol 46(1):62–69CrossRefPubMedGoogle Scholar
- Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG (2003) Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 8(7):673–679. doi: 10.1038/sj.mp.4001270 CrossRefPubMedGoogle Scholar